GSK and Empirico Collaborate on Oligonucleotide Candidate
GSK plc and Empirico Inc. have entered into a worldwide exclusive license agreement for EMP-012, a highly selective siRNA oligonucleotide.
EMP-012 addresses a novel therapeutic target and is currently in a phase I trial for the treatment of chronic obstructive pulmonary disease (COPD), with potential expansion into other inflammatory respiratory diseases.
Medical need in COPD remains high despite ongoing innovation.
The collaboration aims to treat respiratory diseases using EMP-012, a first- and potentially best-in-class siRNA.
Author's summary: GSK and Empirico collaborate on oligonucleotide candidate.More News
- Commuters hot under the collar as snow, ice gridlock roads across Seoul
- Tunbridge Wells gridlocked as residents queue for fresh water after five-day outage
- Breaking: Loyalist troops foil coup attempt in Benin
- Delegates delayed at Brynglas Tunnels is Drakeford's fault
- Hundreds stranded after IndiGo canceled 1,000 flights in India air travel chaos
- No quick fix for ‘tiresome’ M50 gridlock, Minister says
- Après la tentative de coup d'Etat au Bénin, la menace du pouvoir kaki plus présente que jamais en Afrique
- Benin coup attempt foiled by loyalist troops, interior minister says
- Sydney Sixers Vs Adelaide Strikers, WBBL 2025: SYS-W Beat AS-W By One Run Thanks To Ellyse Perry Century
- Women’s Big Bash League 2025-26 results